EcoDrugPlus


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

MOLECULE TYPE: Small molecule

MECHANISMS OF ACTION: Thyroid hormone receptor beta-1 agonist

ROUTE OF ADMINISTRATION: Unknown

STATUS: Investigational

THERAPEUTIC AREA: Unknown

THERAPEUTIC INDICATION: Hypercholesterolemia; Hyperlipidemias; Non-alcoholic Fatty Liver Disease

MOLECULE TYPE: Small molecule

MECHANISMS OF ACTION: Unknown

ROUTE OF ADMINISTRATION: Unknown

STATUS: Investigational

THERAPEUTIC AREA: Unknown

THERAPEUTIC INDICATION: Lymphoma; Neoplasms

MOLECULE TYPE: Small molecule

MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor

ROUTE OF ADMINISTRATION: Unknown

STATUS: Investigational

THERAPEUTIC AREA: Unknown

THERAPEUTIC INDICATION: Infections

MOLECULE TYPE: Small molecule

MECHANISMS OF ACTION: Unknown

ROUTE OF ADMINISTRATION: Unknown

STATUS: Approved

THERAPEUTIC AREA: Unknown

THERAPEUTIC INDICATION: Severe Acute Respiratory Syndrome; Schizophrenia; Malaria


Download Option


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).